OGYÉI Authorisation in Hungary: How to Supply Indian Generic Pharmaceuticals

Why Hungarian buyers look to India for generics

Hungary has a mature pharmaceutical market with strong price pressure in hospital procurement, retail pharmacy and reimbursed generics. Importers and wholesalers are looking for dependable supply, stable pricing and a wider choice of molecules. India is one of the world's largest generic producers, and a well-run sourcing programme can add value on cost, portfolio breadth and capacity for repeat batches.

Hungary is an EU member state, so this is not a simple import of finished goods. Your supply chain has to meet EU pharmaceutical law as applied by the Hungarian regulator. This guide explains the practical steps. Tuli Enterprise is a New Delhi-based merchant exporter supplying buyers in 95+ countries, and we see the same pattern in regulated European markets: planning the regulatory route first saves months later.

The regulator and the legal framework

The national competent authority is the National Institute of Pharmacy and Nutrition, known by its Hungarian acronym OGYÉI. It handles national marketing authorisations, variations, and many procedures involving import and distribution. Medicines can also reach Hungary through EU-wide routes coordinated by the European Medicines Agency.

Broadly, a medicine can be placed on the Hungarian market through:

• National procedure: a marketing authorisation (MA) granted by OGYÉI for Hungary only.
• Mutual recognition or decentralised procedure: an authorisation shared across several EU states, with Hungary as one concerned member state.
• Centralised procedure: an EU-wide authorisation, mainly for specific product categories.

Without a valid MA for the exact product, a generic cannot be commercially supplied. Buyers should confirm current procedures, fees and timelines directly with OGYÉI, as requirements change.

Who holds what: the roles in an EU import chain

Many first-time buyers ask whether an Indian exporter can simply ship to a Hungarian distributor. In practice, several EU-defined roles must be in place:

1. Marketing Authorisation Holder (MAH): the legal entity responsible for the product on the market, established in the EU/EEA.
2. Importer with a manufacturing/import authorisation: a licensed site in the EU/EEA that imports from a non-EU country and performs quality control testing as required.
3. Qualified Person (QP): certifies each batch before release onto the EU market.
4. Wholesale distributor: holds a wholesale distribution authorisation and follows Good Distribution Practice.

Your own licence determines which of these functions you can perform. If you are a wholesaler without import authorisation, you will need an arrangement with a licensed importer or the MAH.

Manufacturing standards for Indian partner facilities

EU law requires medicines to be made under GMP equivalent to EU standards. For Indian-made products, buyers typically expect evidence that the manufacturing site complies with EU GMP, such as a GMP certificate issued after an inspection by an EU authority, together with the required written confirmation and QP oversight. Tuli Enterprise does not manufacture or hold certifications itself; we work with GMP-certified manufacturing partners and help buyers collect the documents their regulator and QP will ask for. Always verify a site's current status directly with the relevant authority.

Typical document pack for Hungary

Exact requirements depend on the route and the product, but a buyer should plan for:

• CTD-format dossier (Modules 1 to 5) for the marketing authorisation, including quality, non-clinical and clinical or bioequivalence data
• Certificate of Pharmaceutical Product (COPP) and Free Sale Certificate where relevant
• Certificate of Analysis (CoA) for each batch
• Stability data aligned with ICH zone conditions
• Manufacturing site GMP documentation and batch manufacturing records for QP review
• Summary of Product Characteristics, patient leaflet and label artwork
• Commercial invoice, packing list, airway bill or bill of lading

Tuli Enterprise can supply COPP, CoA, CTD dossiers, Free Sale Certificate and stability data. For a broader explanation of how these fit together, read our guide to pharmaceutical import documentation.

Labelling, language and serialisation

Packaging for the Hungarian market must follow EU labelling rules and the approved product information. Expect Hungarian-language patient leaflets and labels, and EU safety features (unique identifier and anti-tampering device) for prescription medicines under the Falsified Medicines framework. Packaging is often completed or finalised in the EU by the licensed importer, so agree early who is responsible for artwork, serialisation and secondary packaging. If you need dedicated presentations or a private-label portfolio, our contract manufacturing service can coordinate with partner plants.

Choosing products that make commercial sense

Not every molecule is worth pursuing. Hungary's reimbursement system, tender cycles and existing generic competition all affect margins. Focus on:

• Products with an off-patent reference medicine and clear bioequivalence pathways
• Molecules where local supply is thin or prices are under pressure
• Hospital-use injectables and oral solids with predictable demand
• Therapy areas where you already have customers

You can browse our product catalogue and explore options by therapeutic category to shortlist candidates before opening a dossier discussion.

MOQ, lead time and pricing

Minimum order quantities depend on the product, pack type and whether it is a stock item or a made-to-order batch. For registered or dossier-supported programmes, the first commercial order is usually larger than a sample or trial order. Lead times vary: stock or standard items ship faster, while new artwork, validation batches or EU-specific packaging add time. We give realistic timelines per RFQ rather than generic promises. Agree Incoterms (FCA, CIF or DAP) at the start, and confirm payment terms, batch size and shelf-life on arrival, since remaining shelf-life matters for hospital and pharmacy acceptance.

A practical step-by-step plan

1. Define your role: MAH, importer, wholesaler or tender supplier.
2. Shortlist molecules and strengths, checking the current Hungarian market and reference products.
3. Request dossier availability, COPP, GMP site documents and sample CoAs.
4. Confirm the registration route with OGYÉI and your regulatory consultant.
5. Agree specifications, packaging, labelling and serialisation responsibilities.
6. Place a pilot order, with QP release at your EU-licensed site.
7. Scale to repeat orders with a forecast and agreed lead times.

You can also compare how other markets handle similar steps on our country guides page.

Common pitfalls to avoid

• Assuming a dossier prepared for another market will be accepted unchanged in the EU
• Ordering commercial volumes before the MA and QP release arrangements are confirmed
• Overlooking shelf-life, language and serialisation requirements
• Working with suppliers who cannot document the manufacturing site's current inspection status

Request a quote or dossier review

If you are a Hungarian importer, distributor or hospital supplier evaluating Indian generics, Tuli Enterprise can help you map documents, shortlist products and prepare a quotation. Send your product list and target volumes through our contact page, message us on WhatsApp at wa.me/919654308142, or email [email protected]. Please confirm all current registration and import requirements with OGYÉI before committing to a purchase.